133 related articles for article (PubMed ID: 12053814)
1. [Graft vs. tumor effect in chronic granulocytic leukemia].
Ruiz-Argüelles GJ
Rev Invest Clin; 2002; 54(2):154-60. PubMed ID: 12053814
[No Abstract] [Full Text] [Related]
2. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Perel JM; McCarthy C; Walker O; Irving I; Williams B; Kennedy GA
Haematologica; 2005 Nov; 90 Suppl():ECR25. PubMed ID: 16266916
[No Abstract] [Full Text] [Related]
3. Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib.
Prebet T; Tigaud I; Hayette S; Clapisson G; Philip I; Michallet M; Nicolini FE
Haematologica; 2005 Nov; 90 Suppl():ECR36. PubMed ID: 16266927
[No Abstract] [Full Text] [Related]
4. Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
Gopcsa L; Barta A; Banyai A; Foldi J; Kalasz L; Pajor L; Gidali J; Regeczy N; Paloczi K
Acta Haematol; 2001; 106(3):100-5. PubMed ID: 11713374
[TBL] [Abstract][Full Text] [Related]
5. The management of chronic myeloid leukaemia--a case history.
Sureda A; Hernández-Bronchud M
Ann Oncol; 1997 Jan; 8(1):91-6. PubMed ID: 9093713
[No Abstract] [Full Text] [Related]
6. Bcr-Abl inhibition as a modality of CML therapeutics.
Buchdunger E; Matter A; Druker BJ
Biochim Biophys Acta; 2001 Aug; 1551(1):M11-8. PubMed ID: 11553417
[No Abstract] [Full Text] [Related]
7. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
[TBL] [Abstract][Full Text] [Related]
8. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Berger U; Hehlmann R
Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
[No Abstract] [Full Text] [Related]
9. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Schaefer UW
Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
[TBL] [Abstract][Full Text] [Related]
10. Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias.
Gupta V; Kamel-Reid S; Minden MD; Lipton JH; Brandwein J; Messner HA
Hematology; 2003 Jun; 8(3):139-43. PubMed ID: 12745646
[TBL] [Abstract][Full Text] [Related]
11. Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
Maury S; Belhadj K; Chami I; Kuentz M; Cordonnier C; Bories D
Bone Marrow Transplant; 2001 Oct; 28(7):717-20. PubMed ID: 11704798
[TBL] [Abstract][Full Text] [Related]
12. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
13. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
[TBL] [Abstract][Full Text] [Related]
14. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
15. [Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Boqué C; Grañena A
Sangre (Barc); 1998 Apr; 43(2):155-63. PubMed ID: 9656777
[No Abstract] [Full Text] [Related]
16. Prolonged molecular remission in advanced phase of chronic myeloid leukemia using combination of imatinib and high-dose chemotherapy.
Saulnier PJ; Dalbiès F; Berthou C; Guilhot F; Bourmeyster N; Chomel JC; Thuran A
Leuk Lymphoma; 2008 Apr; 49(4):815-6. PubMed ID: 18398751
[No Abstract] [Full Text] [Related]
17. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Wassmann B; Klein SA; Scheuring U; Pfeifer H; Martin H; Gschaidmeier H; Hoelzer D; Ottmann OG
Bone Marrow Transplant; 2001 Oct; 28(7):721-4. PubMed ID: 11704799
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
19. Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate.
Johnson NA; Fetni R; Caplan SN
Leuk Lymphoma; 2005 Apr; 46(4):629-30. PubMed ID: 16019496
[No Abstract] [Full Text] [Related]
20. [Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].
Tauchi T
Rinsho Ketsueki; 2004 Jan; 45(1):23-31. PubMed ID: 14999931
[No Abstract] [Full Text] [Related]
[Next] [New Search]
